<DOC>
	<DOCNO>NCT00875160</DOCNO>
	<brief_summary>This open-label study design ass AT2101 safe patient Gaucher disease AT2101 get body take mouth . The study offer adult patient type 1 Gaucher disease currently receive stable dose enzyme replacement therapy ( ERT ) imiglucerase . During study , subject receive ERT ( 35 day ) . The study consist screen period ( ~14 day ) , treatment period ( 12 day ) follow-up period ( 7 day last dose ) . At two point study , subject house in-patient treatment facility 3 days/2 night accommodate necessary blood draw .</brief_summary>
	<brief_title>A Study Type 1 Gaucher Patients Evaluate Pharmacokinetics , Safety Pharmacodynamics AT2101</brief_title>
	<detailed_description>While study , subject require refrain consume follow food beverage : - Caffeine : 24 hour admission throughout in-patient stay ; - Alcohol : 48 hour admission throughout in-patient stay . A maximum 2 units/day allow out-patient part study ( 1 unit alcohol = wind ( 125mL ) =spirits ( 25mL ) =beer ( 284mL ) ; - Vitamins : throughout in-patient period . Subjects also restrict take medication herbal product study except Principal Investigator permit . Subjects engage strenuous activity time in-patient period .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Have confirm diagnosis type 1 Gaucher disease document gene mutation ; Clinically stable stable dose ERT least 2 year study entry , change dose level regimen last 6 month ; Willing stop ERT duration study ; Male female age 18 65 inclusive ; All subject reproductive potential require practice acceptable method contraception ; All subject must body mass index less 30 ; Provide write informed consent participate study . A clinically significant disease , severe complication Gaucher disease , serious intercurrent illness may preclude participation study opinion Investigator ; During screening/wash period , clinically significant finding , base physical exam , medical history review , lab assessment , vital sign assessment and/or significant finding would compromise safety subject , preclude subject complete study deem Investigator ; Partial total splenectomy ; History pulmonary hypertension Gaucherrelated lung disease ; History allergy sensitivity study drug excipients , include prior serious allergic reaction iminosugars ; Screening Day 1 ( dose ) 12lead ECG demonstration QTc &gt; 450 msec male &gt; 470 female ; Pregnant breastfeeding ; Current/recent drug alcohol abuse within past 12 month ; Treatment investigational product , include investigational form ERT , 90 day study entry ; Treatment previous 90 day drug know welldefined potential toxicity major organ ; Presence sequelae gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug ; Subject otherwise unsuitable study opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>